anthonyyazdaniml/CT-ADE-SOC huggingface dataset:
Intervention: Lapatinib
Trial phase: Early Phase 1
ATC code: L01EH01 | L01XE07
SMILES: CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 19
Group description: Subjects received lapatinib 1500 mg by mouth for 10 days prior to surgery for vestibular schwannoma resection.
Eligibility criteria:
Inclusion Criteria:

Meet diagnostic criteria for NF2 including presence of bilateral VS or idiopathic VS without evidence of genetic syndrome.
VS surgery determined clinically necessary by the treating physician and scheduled within 4 weeks.
Normal cardiac left ventricular ejection fraction (LVEF) by multiple-gated acquisition (MUGA) scan or transthoracic echocardiogram.
Karnofsky performance status 60% (i.e. the patient must be able to care for himself/herself with occasional help from others).
Must have the following hematologic, renal and liver function: Absolute neutrophil count ≥ 1,000/mm³ (unsupported); platelet count ≥ 75,000/mm³ (unsupported); hemoglobin ≥ 8 g/dL (transfusion support allowed); Creatinine ≤ 1.5 times upper limit of normal (ULN) OR glomerular filtration rate ≥ 70 ml/min; Bilirubin ≤ 1.5 times ULN; ALT ≤ 2.5 times ULN.
Be able to provide written informed consent.
Any neurologic deficits must be stable for ≥ 1 week.
Be able to swallow tablets.
Subjects with the potential for pregnancy or impregnating their partner must agree to follow acceptable birth control methods to avoid conception. Women of childbearing potential must have a negative pregnancy test.
Suspend the use of P450 inducing or P450 suppressing agents for a minimum of 10 days prior to starting lapatinib.

Exclusion Criteria:

Serious concurrent infection or medical illness, which would jeopardize the ability of the patient to receive the treatment outlined in this protocol with reasonable safety.
Pregnant or breast-feeding.
Receiving concurrent therapy for their tumor (i.e. chemotherapeutics or investigational agents, radiation or immunotherapy) within 4 weeks of the first dose of the study drug.
Concurrent or prior malignancy, other than curatively treated carcinoma-in-situ or basal cell carcinoma of the skin. Subjects who have been free of disease (any prior malignancy) for five years are eligible for this study.
Received cytochrome P450-inducing anticonvulsants (EIADs; e.g., phenytoin, carbamazepine, phenobarbital, primidone, oxcarbazepine) or similar agents (e.g., rifampin) or P450 inhibiting agents (Ketoconazole, Itraconazole, Clarithromycin, Atazanavir, Indinavir, Nefazodone, Nelfinavir, Ritonavir, Saquinavir, Telithromycin, Voriconazole) within 10 days prior to starting lapatinib.
Significant gastrointestinal disorder(s)(e.g., Crohn's disease, ulcerative colitis, extensive gastric resection).
Neurologic deficits that are rapidly progressing.
Known cardiac disease (either arrhythmia or congestive heart failure) requiring treatment.
Intervention: Pyrimethamine
Trial phase: Not Applicable
ATC code: P01BD01 | P01BD51 | P01BF04 | P01BF09
SMILES: CCc1nc(N)nc(N)c1-c1ccc(Cl)cc1
Sex: Male
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 135
Group description: belladonna 16.2 mg and opium 60 mg suppository
Eligibility criteria:
Inclusion Criteria:

Patients scheduled for laparoscopic radical prostatectomy at Virginia Mason, who do not have chronic pain or allergies to opioid analgesics are eligible for this study.

Exclusion Criteria:

Women are excluded due to the absence of a prostate.
Children are excluded due to the absence of prostate cancer in this group.

Patients meeting any of the following will not be eligible for the study:

Patients at risk for complications from anticholinergic agents including those with a history of glaucoma, bronchial asthma, convulsive disorder, or high risk for delirium
History of previous allergies or adverse reactions to belladonna and opium and/or opioid analgesics
History of chronic pain or chronic use of opioid and nonopioid analgesics
History of alcohol or opioid dependency/abuse within last three months
Intervention: Pemetrexed
Trial phase: Phase 2
ATC code: L01BA04
SMILES: Nc1nc(=O)c2c(CCc3ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc3)c[nH]c2[nH]1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 15
Group description: pemetrexed
Eligibility criteria:
Inclusion Criteria:

Histologically confirmed adenocarcinoma of the pancreas
Prior treatment for distant or locally advanced disease with gemcitabine-based therapy
Measurable or evaluable disease
ECOG performance status 0-2
Adequate hematological parameters
Adequate baseline liver function
At least 28 days from any major surgery
At least 2 weeks from the last radiation treatment
Must have recovered from reversible toxicities of prior chemotherapy
Must be able to discontinue any nonsteroidal anti-inflammatory medications
Must be willing to receive intramuscular vitamin B12 shots and take oral folate supplements

Exclusion Criteria:

Any prior treatment with pemetrexed
More than one prior chemotherapy regimen
HIV positive on antiretroviral therapy
Pregnant or lactating
Prior organ allograft
On concurrent antitumor therapy including radiation therapy or other chemotherapies
Creatinine clearance 45 ml/min or less
Absolute neutrophil count < 1500
Platelets < 75,000
Bilirubin > 1.5 times the upper limit of normal
Transaminases > 3 times the upper limit of normal except in known liver metastasis wherein they may be </= 5 times upper limit of normal
Clinically significant ascites or pleural effusion that cannot be drained
Any medical or psychiatric condition that may interfere with the ability to comply with protocol treatment
Intervention: Tyrosine
Trial phase: Not Applicable
SMILES: N[C@@H](Cc1ccc(O)cc1)C(=O)O
Sex: All
Age groups: Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 2
Group description: Healthy men and women with different haplotypes will receive an infusion of leucine and tyrosine. The following day they begin a 5 day course of dichloroacetate (DCA)at a dose of 2.5mcg/kg/day. On day 6 they return and receive another infusion of leucine and tyrosine. After a 30 day washout period the subject returns and again receives an infusion of leucine and tyrosine. Then on day 2 they begin a dose of DCA at 25mg/kg for 5 days and then return for the final infusion of leucine and tyrosine.
Eligibility criteria:
Inclusion Criteria:

Adults scheduled for elective surgery for benign liver disease.
Normal EKG and history
Normal baseline labs

Exclusion Criteria:

Pregnancy
severe anemia, defined as a hematocrit < 30%.
diabetes mellitus
renal insufficiency, defined as a serum creatinine > 1.5 mg/dl or a creatinine clearance < 60 ml/min
elevated liver enzymes
psychiatric illness requiring medication
primary biliary cirrhosis or any other form of cirrhosis
viral hepatitis or non-viral steatohepatitis
coronary heart disease, defined as requiring daily administration of anti-anginal drugs or as New York Heart Association Class III or IV heart failure
malignancy of any type in any anatomical location
Intervention: Cetrorelix
Trial phase: Phase 4
ATC code: H01CC02
SMILES: CC(=O)N[C@H](Cc1ccc2ccccc2c1)C(=O)N[C@H](Cc1ccc(Cl)cc1)C(=O)N[C@H](Cc1cccnc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H](CCCNC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O
Sex: Female
Age groups: Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 308
Group description: Early fixed start of a daily dose of 0.25mg Cetrotide on cycle day 2, together with the initiation of daily treatment with exogenous gonadotropins.
Eligibility criteria:
Inclusion Criteria:

Normo-ovulatory women < 39 years with an indication for IVF or ICSI

Exclusion Criteria:

More than 2 previous unsuccessful IVF/ICSI cycles
BMI > 32 kg/m2
Intervention: Cetrorelix
Trial phase: Phase 4
ATC code: H01CC02
SMILES: CC(=O)N[C@H](Cc1ccc2ccccc2c1)C(=O)N[C@H](Cc1ccc(Cl)cc1)C(=O)N[C@H](Cc1cccnc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H](CCCNC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O
Sex: Female
Age groups: Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 309
Group description: Late fixed start of a daily dose of 0.25mg Cetrotide on cycle day 6. As in the other arm of the study, exogenous gonadotropins will commence on cycle day 2.
Eligibility criteria:
Inclusion Criteria:

Normo-ovulatory women < 39 years with an indication for IVF or ICSI

Exclusion Criteria:

More than 2 previous unsuccessful IVF/ICSI cycles
BMI > 32 kg/m2
Intervention: Ezetimibe
Trial phase: Phase 3
ATC code: C10AX09 | C10BA02 | C10BA05 | C10BA06 | C10BA10 | C10BA11 | C10BA12
SMILES: [H][C@]1(CC[C@H](O)c2ccc(F)cc2)C(=O)N(c2ccc(F)cc2)[C@]1([H])c1ccc(O)cc1
Sex: All
Age groups: Child
Healthy volunteers: No
Participants at risk: 92
Group description: Ezetimibe 10-mg tablet once daily for 12 weeks
Eligibility criteria:
Inclusion Criteria:

Each subject may be of either sex and of any race/ethnicity, and must be >=6 and <=10 years of age, with a diagnosis of primary hypercholesterolemia (heterozygous familial or nonfamilial) despite being on a lipid-lowering diet for at least 3 months with a LDL-C of >159mg/dL
Each subject's parent/guardian must be willing to give written informed consent on his/her behalf.

Exclusion Criteria:

Each subject must not:

Have known hypersensitivity or any contraindication to ezetimibe.
Have use of any investigational drugs within 30 days of study entry.
Be a member or a family member of the personnel of the investigational or sponsor staff directly involved with this trial.
Be a female of child-bearing potential who is pregnant, intends to become pregnant, or is nursing
Have known congenital cardiac disorder.
Have documented or laboratory values consistent with homozygous familial hypercholesterolemia (HoFH).
Be known to be human immunodeficiency virus (HIV) positive.
Intervention: Mifepristone
Trial phase: Phase 3
ATC code: G03XB01 | G03XB51
SMILES: [H][C@@]12CC[C@@](O)(C#CC)[C@@]1(C)C[C@H](c1ccc(N(C)C)cc1)C1=C3CCC(=O)C=C3CC[C@]12[H]
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 4
Group description: Receive 600 or 1200 mg/ day of mifepristone for 8 days

Mifepristone (RU-486)
Eligibility criteria:
Inclusion Criteria:Inclusion criteria for PMD (individuals with Psychotic Major Depression) are as follows:

DSM IV diagnosis of Major Depressive Disorder with psychotic features, Bipolar II Disorder with psychotic features in a major depressive episode.
21-item HAM-D score greater than or equal to 21.
Thase Core Endogenomorphic Scale score greater than or equal to 6 on the items included in the 21-item HDRS.
Between 21 - 85 years of age.
Female patients of child bearing capacity with Psychotic Depression receiving treatment with mifepristone are required to use a double-barrier method of contraception or abstinence for the entire duration of the study as well as for thirty days after the last dose of Mifepristone is taken.
If currently taking antipsychotic, antidepressant, anticonvulsant, and/or mood-stabilizing medications, must be stable on the medication for at least one-week prior to entering the study.
Pre-existing (current) primary treating psychiatrist for subjects with psychotic features.
Any secondary diagnoses from the anxiety disorder spectrum is acceptable. Any secondary diagnoses from the anxiety disorder spectrum is acceptable. Primary pre-existing chronic Obsessive-Compulsive Disorder(OCD) will be an exclusion criteria. Exclusion Criteria:Exclusion criteria for PMDs are as follows:

1. ECT in the 6 months prior to the study. 2. Abuse of drugs or alcohol in the 6 months prior to study. 3. Unstable or untreated hypertension, cardiovascular disease. 4. If participating in the blood draw portion of the protocol, endocrine disorders are exclusionary. 5. Use of additional prescription medications, street drugs, or alcohol during the week before the study. 6. Previous mifepristone failure or non-response. 7. Any Axis II diagnosis or traits which would make participation in the study difficult. 8. Current pregnancy or lactation.
Intervention: Cetrorelix Acetate
Trial phase: Not Applicable
SMILES: CC(=O)NC(Cc1ccc2ccccc2c1)C(=O)NC(Cc1ccc(Cl)cc1)C(=O)NC(Cc1cccnc1)C(=O)NC(CO)C(=O)NC(Cc1ccc(O)cc1)C(=O)NC(CCCNC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NC(C)C(N)=O.CC(=O)O.CC(=O)O
Sex: Female
Age groups: Adult
Healthy volunteers: No
Participants at risk: 20
Group description: oocyte donors will receive cetrotide acetate on the day of oocyte retrieval. The incidence of OHSS will be assessed.
Eligibility criteria:
Inclusion Criteria:

Prospective donors with BMIs between 19 and 28,
Those with normal FSH levels and good antral follicle counts between 19-28 years of age, AND
Donors would have passed all the required testing as mandated by VCRM and the FDA.

Exclusion Criteria:

Oocyte donors exceeding a BMI of > 28,
Those with any communicable diseases,
Those with low antral follicle counts and small ovarian volumes,
Those with elevated FSH levels,
Those with positive sickle cell screen or cystic fibrosis screening,
Smokers, OR
Donors who are unable or unwilling to follow the research protocols.
Intervention: Sulfamethoxazole
Trial phase: Not Applicable
ATC code: G01AE10 | J01EC01 | J01EE01 | J04AM08
SMILES: Cc1cc(NS(=O)(=O)c2ccc(N)cc2)no1
Sex: All
Age groups: Child
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 140
Group description: Incision and drainage of the abscess and treatment with oral TMP-SMX (100 patients)

Trimethoprim-sulfamethoxazole: 10mg/kg/day (based on trimethoprim component), divided twice daily for ten days (maximum dose: 160mg (TMP component) per dose)
Eligibility criteria:
Inclusion Criteria:

Age 3 months to 17 years
Single, localized soft tissue abscesses requiring incision and drainage with purulent material obtained
Diameter of the abscess less than 5cm as measured by the treating physician

Exclusion Criteria:

Signs of systemic illness or ill-appearing, as determined by the treating physician
Admission to the hospital following treatment in the Emergency Department
Known sulfa allergy
Immunocompromised patients
Soft tissue abscesses involving the perineum (labia, scrotum, penis, perirectal)
Previous antibiotic use (for any reason) in the past seven days
Non-English speaking patients and families
Intervention: Ketorolac
Trial phase: Phase 4
ATC code: M01AB15 | S01BC05 | S01FB51
SMILES: O=C(c1ccccc1)c1ccc2n1CCC2C(=O)O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 30
Group description: Intraoperative local infiltration analgesia (ropivacaine 300 mg, epinephrine 0.5 mg and ketorolac 30 mg) After surgery,eight intra-articular bolus doses of ropivacaine 100 mg with 15 mg ketorolac
Eligibility criteria:
Inclusion Criteria:

Total knee arthroplasty
Age > 18
Tolerance for study drugs
Written informed consent

Exclusion Criteria:

-
Intervention: Gemcitabine
Trial phase: Phase 2
ATC code: L01BC05
SMILES: Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 32
Group description: Chemotherapy Treatment with Gemcitabine, Docetaxel, and Capecitabine (GTX) and weekly radiation therapy with low-dose Gemzar chemotherapy.
Eligibility criteria:
Inclusion Criteria:

Histologically confirmed adenocarcinoma of pancreas localized to the pancreas, small bowel, stomach and/or encasing the superior mesenteric artery, vein or portal vein. (a.k.a. Stage IV A).
No prior chemotherapy for their pancreatic cancer or radiation to the area of the tumor.
Measurable disease: Any mass reproducibly measurable in two perpendicular diameters by x-ray, physical examination, CT or MRI scans.
Ineligible for other high priority national or institutional studies
Whipple surgery not allowed. Prior surgery is allowed as long as it was not pancreatic resection (i.e. Whipple surgery) and the time from surgical recovery is greater than three weeks.
Non pregnant females who are not breast feeding with a negative serum β-HCG test within 1 week of starting the study. Men and women of childbearing potential must be willing to consent to using effective contraception while on treatment and for a reasonable period thereafter.

Clinical Parameters

Life expectancy > 2 months.
Age 18 to 70 years old
Performance status 0-2 (ECOG). (See Appendix IV)
Peripheral Neuropathy must be < grade 1
Able to tolerate oral medications
Absolute Neutrophil Count > 1,500 μl
White Blood Count > 3,000/μl
Platelet count > 100,000/μl
BUN < 1.5 x normal
Creatinine < 1.5 normal
Hemoglobin > 8.0 g/dl
Serum Albumin > 2.5 mg/dl
Total Bilirubin < 5.0 mg/dl
SGOT, SGPT, Alkaline Phosphatase < 4.0 x ULN

Exclusion Criteria:

Hypersensitivity: Patients with a history of severe hypersensitivity reaction to Taxotere® or other drugs formulated with polysorbate 80 must be excluded.
Informed Consent: Each patient must be completely aware of the nature of his/her disease process and must willingly give consent after being informed of the experimental nature of the therapy, alternatives, potential benefits, side-effects, risks, and discomforts.
Prior malignancies in last 5 years other than: curatively treated carcinoma in-situ of the cervix, non-melanoma skin cancer, prostate or DCIS (ductal carcinoma in-situ) previously treated successfully (cancer free)
No serious medical or psychiatric illness preventing informed consent or intensive treatment (e.g., serious infection).
Patients known to have HIV will be excluded.
Patients cannot have received any prior investigational agent/therapy, nor will they be allowed any investigational agent/therapy while on protocol.
Intervention: RISEDRONIC ACID
Trial phase: Phase 4
ATC code: M05BA07 | M05BB02 | M05BB04 | M05BB07
SMILES: O=P(O)(O)C(O)(Cc1cccnc1)P(=O)(O)O
Sex: Male
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 80
Group description: Active drug

Risedronate: 35 mgs/week + calcium and vit d
Eligibility criteria:
Inclusion Criteria:

Male gender
Epilepsy
Anti-epileptic drug treatment with phenytoin, or phenobarbital or valproate sodium
Normal renal function and normal Vitamin D and calcium levels

Exclusion Criteria:

Female gender
Organ transplant
Use of oral glucocorticoids
Renal insufficiency (eGFR < 30ml/min)
Severe swallowing disorder
Severe esophagitis
Patients taking sodium valproate for reasons other than epilepsy
Previous treatment with osteoporosis drugs such as bisphosphonates, calcitonin or PTH analog
Intervention: Etravirine
Trial phase: Phase 1
ATC code: J05AG04
SMILES: Cc1cc(C#N)cc(C)c1Oc1nc(Nc2ccc(C#N)cc2)nc(N)c1Br
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 28
Group description: Healthy volunteers receiving etravirine 200mg orally twice daily
Eligibility criteria:
Inclusion Criteria:

18 years of age or older
Negative ELISA for HIV-1 or HIV-2 at screening
Negative hepatitis B surface antigen at screening
Negative hepatitis C antibody at screening
For women of reproductive potential, a negative urine pregnancy test at screening and willingness to use two forms of birth control during the course of the study
No history of diabetes, hypertension, or dyslipidemia
No anticipated changes or additions to other medical therapies during the course of the study

Exclusion Criteria:

Inability to provide written, informed consent
Known allergy/intolerance to etravirine or nitroglycerin
Absolute neutrophil count < 750cell/mL at screening
Hemoglobin <11g/dL at screening
Platelet count <100,000/mL at screening
Estimated creatinine clearance (per Cockcroft-Gault equation) <55 mL/min at screening
Liver transaminases (AST or ALT) > 100 IU/mL or total bilirubin > 1.5mg/dL at screening
Breastfeeding at screening and during the course of the study
Hypotension, defined as SBP<90mmHg at time of each main study visit before brachial artery ultrasound measurements
Receipt of investigational agents, cytotoxic chemotherapy, systemic glucocorticoids (>10mg/day of prednisone or the equivalent), or anabolic steroids within 30 days of each screening visit or each main study visit
Use of sildenafil (Viagra or Silagra), vardenafil (Levitra), or tadalafil (Cialis), within 72 hours (before or after) of brachial artery reactivity testing
Indwelling vascular catheters within any upper body vessel at time of brachial artery reactivity testing
Active drug or alcohol use or dependence that, in the opinion of the investigator, would interfere with adherence to study requirements
Acute therapy for serious infection or other serious medical illnesses (in the judgment of the site investigator) requiring systemic treatment and/or hospitalization within 14 days prior to each screening and study visit
History of migraine headaches
History of Raynaud's phenomenon
History of cardiac arrythmias
History of hypothyroidism or hyperthyroidism that is untreated (defined as a TSH outside the normal range on most recent testing during normal clinical care)
History of carotid bruits.
History of any tobacco use (cigarette smoking, cigar smoking, chewing tobacco) or nicotine replacement treatments (patch, gum) within one year of screening.
Intervention: Atorvastatin
Trial phase: Phase 4
ATC code: C10AA05 | C10BA05 | C10BX03 | C10BX06 | C10BX08 | C10BX11 | C10BX12 | C10BX15 | C10BX18 | C10BX19
SMILES: CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 46
Group description: Participants with hypercholesterolemia receiving atorvastatin 20 mg for 12 weeks after a 4-week washout and 4 weeks of daily atorvastatin 10 mg
Eligibility criteria:
Inclusion Criteria:

atorvastatin 10 mg monotherapy for 4 weeks or longer before the start of the 4-week washout and low density lipoprotein-cholesterol (LDL-C) levels that had not reached the following lipid management target values during treatment: Category I (low-risk group) with no other risk factors - LDL-C <160 mg/dL; Category II (mid-risk group) with 1-2 risk factors other than LDL-C levels - LDL-C <140 mg/dL; Category III (high-risk group) with 3 or more other risk factors - LDL-C <120 mg/dL; and for participants with history of coronary artery disease - LDL-C <100 mg/dL.
outpatient men or women, age 20 years and older

Exclusion Criteria:

fasted triglyceride level at the start of washout or treatment period exceeding 400 mg/dL.
homozygous familial hypercholesterolemia.
creatine phosphokinase (CPK) >2 times the upper limit of normal (X ULN) at start of washout or treatment period.
glycosylated hemoglobin (HbA1c) >=8％ at start of washout or treatment period.
severe hepatic function disorder, or aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >2X ULN at start of washout or treatment period.
hypersensitivity to ezetimibe, atorvastatin, or rosuvastatin tablets.
pregnant or lactating
discontinued use of atorvastatin 10 mg for less than 4 weeks at start of treatment period (however, if participant had taken atorvastatin 10 mg before the test conducted at the start of the observation period, a period of discontinuation of 27 days is allowed.)
cyclosporine treatment
hyperlipidemia associated with hypothyroidism, obstructive gall bladder or biliary disease, chronic renal failure, and/or pancreatitis.
hyperlipidemia associated with drug administration that causes adverse serum lipid effects.
participation in a clinical study within 4 weeks of washout
cancer or cancer history within previous 5 years, except for successfully treated basal cell carcinoma of the skin.